For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
433
views
817
references
 Top references
cited by
2,564
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    16
    shares
      1,502
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer.

          Related collections

          Most cited references817

          • Record: found
          • Abstract: found
          • Article: not found

          BRAF mutation in thyroid cancer.

          M Xing (2005)
          Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon which novel approaches to the management of thyroid cancer can be developed. A recent important genetic finding in thyroid cancer is the oncogenic T1799A transversion mutation of BRAF (the gene for the B-type Raf kinase, BRAF). Since the initial report of this mutation in thyroid cancer 2 years ago, rapid advancements have been made. BRAF mutation is the most common genetic alteration in thyroid cancer, occurring in about 45% of sporadic papillary thyroid cancers (PTCs), particularly in the relatively aggressive subtypes, such as the tall-cell PTC. This mutation is mutually exclusive with other common genetic alterations, supporting its independent oncogenic role, as demonstrated by transgenic mouse studies that showed BRAF mutation-initiated development of PTC and its transition to anaplastic thyroid cancer. BRAF mutation is mutually exclusive with RET/PTC rearrangement, and also displays a reciprocal age association with this common genetic alteration in thyroid cancer. The T1799A BRAF mutation occurs exclusively in PTC and PTC-derived anaplastic thyroid cancer and is a specific diagnostic marker for this cancer when identified in cytological and histological specimens. This mutation is associated with a poorer clinicopathological outcome and is a novel independent molecular prognostic marker in the risk evaluation of thyroid cancer. Moreover, preclinical and clinical evaluations of the therapeutic value of novel specific mitogen-activated protein kinase pathway inhibitors in thyroid cancer are anticipated. This newly discovered BRAF mutation may prove to have an important impact on thyroid cancer in the clinic.
          Article 0 comments Cited 322 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular genetics and diagnosis of thyroid cancer.

            Yuri E. Nikiforov, Marina Nikiforova (2011)
            Thyroid cancer is a common type of endocrine malignancy, and its incidence has been steadily increasing in many regions of the world. Initiation and progression of thyroid cancer involves multiple genetic and epigenetic alterations, of which mutations leading to the activation of the MAPK and PI3K-AKT signaling pathways are crucial. Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements. The mutational mechanisms seem to be linked to specific etiologic factors. Chromosomal rearrangements have a strong association with exposure to ionizing radiation and possibly with DNA fragility, whereas point mutations probably arise as a result of chemical mutagenesis. A potential role of dietary iodine excess in the generation of BRAF point mutations has also been proposed. Somatic mutations and other molecular alterations have been recognized as helpful diagnostic and prognostic markers for thyroid cancer and are beginning to be introduced into clinical practice, to offer a valuable tool for the management of patients with thyroid nodules.
            Article 0 comments Cited 304 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

              Mingzhao Xing, Ali Alzahrani, Kathryn Carson … (2013)
              BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. To investigate the relationship between BRAF V600E mutation and PTC-related mortality. Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile range, 34-58 years) and an overall median follow-up time of 33 months (interquartile range, 13-67 months) after initial treatment at 13 centers in 7 countries between 1978 and 2011. Patient deaths specifically caused by PTC. Overall, mortality was 5.3% (45/845; 95% CI, 3.9%-7.1%) vs 1.1% (11/1004; 95% CI, 0.5%-2.0%) (P < .001) in BRAF V600E-positive vs mutation-negative patients. Deaths per 1000 person-years in the analysis of all PTC were 12.87 (95% CI, 9.61-17.24) vs 2.52 (95% CI, 1.40-4.55) in BRAF V600E-positive vs mutation-negative patients; the hazard ratio (HR) was 2.66 (95% CI, 1.30-5.43) after adjustment for age at diagnosis, sex, and medical center. Deaths per 1000 person-years in the analysis of the conventional variant of PTC were 11.80 (95% CI, 8.39-16.60) vs 2.25 (95% CI, 1.01-5.00) in BRAF V600E-positive vs mutation-negative patients; the adjusted HR was 3.53 (95% CI, 1.25-9.98). When lymph node metastasis, extrathyroidal invasion, and distant metastasis were also included in the model, the association of BRAF V600E with mortality for all PTC was no longer significant (HR, 1.21; 95% CI, 0.53-2.76). A higher BRAF V600E-associated patient mortality was also observed in several clinicopathological subcategories, but statistical significance was lost with adjustment for patient age, sex, and medical center. For example, in patients with lymph node metastasis, the deaths per 1000 person-years were 26.26 (95% CI, 19.18-35.94) vs 5.93 (95% CI, 2.96-11.86) in BRAF V600E-positive vs mutation-negative patients (unadjusted HR, 4.43 [95% CI, 2.06-9.51]; adjusted HR, 1.46 [95% CI, 0.62-3.47]). In patients with distant tumor metastasis, deaths per 1000 person-years were 87.72 (95% CI, 62.68-122.77) vs 32.28 (95% CI, 16.14-64.55) in BRAF V600E-positive vs mutation-negative patients (unadjusted HR, 2.63 [95% CI, 1.21-5.72]; adjusted HR, 0.84 [95% CI, 0.27-2.62]). In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC. Because overall mortality in PTC is low and the association was not independent of tumor features, how to use BRAF V600E to manage mortality risk in patients with PTC is unclear. These findings support further investigation of the prognostic and therapeutic implications of BRAF V600E status in PTC.
              Article 0 comments Cited 272 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Thyroid
                Abbreviated Title: Thyroid
                Publisher: Mary Ann Liebert Inc
                ISSN (Print): 1050-7256
                ISSN (Electronic): 1557-9077
                Publication date Created: January 2016
                Publication date (Print): January 2016
                Volume: 26
                Issue: 1
                Pages: 1-133
                Affiliations
                [1 ]University of Colorado School of Medicine, Aurora, Colorado.
                [2 ]Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
                [3 ]The Mayo Clinic, Rochester, Minnesota.
                [4 ]Boston Medical Center, Boston, Massachusetts.
                [5 ]Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
                [6 ]University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
                [7 ]The University of Siena, Siena, Italy.
                [8 ]Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
                [9 ]University Health Network, University of Toronto, Toronto, Ontario, Canada.
                [10 ]Institute Gustave Roussy and University Paris Sud, Villejuif, France.
                [11 ]Oregon Health and Science University, Portland, Oregon.
                [12 ]University of Texas M.D. Anderson Cancer Center, Houston, Texas.
                [13 ]Duke University School of Medicine, Durham, North Carolina.
                [14 ]University of Cincinnati Medical Center, Cincinnati, Ohio.
                [15 ]Memorial Sloan Kettering Cancer Center, New York, New York.
                [16 ]MedStar Washington Hospital Center, Washington, DC.
                Article
                DOI: 10.1089/thy.2015.0020
                PMC ID: 4739132
                PubMed ID: 26462967
                SO-VID: a2a3fce3-2264-48ef-8acf-a94b53c4bbbf
                Copyright © © 2016
                License:

                https://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content1,502

                See all similar

                Cited by3,795

                See all cited by

                Most referenced authors11,225

                See all reference authors